Both types of diabetes mellitus (DM) are recognized by the destruction of pancreas or deficient function of Islets' cells causing several complications. Diabetes mainly affect the kidney leading to diabetic nephropathy (DN) in the late renal stage, which caused higher mortality in diabetic patients. Since diabetic disease appearance, nephropathy may be observed in patients with type 1 or 2 diabetes. Recently, cell culture can be used in the regenerative medicine as a new method for treating diabetes and DN. Therefore, the aim of the current study was to prove the beneficial effect of mesenchymal stromal cells (MSCs) transplantation on DN during the early stage. Male rats were randomized in 3 groups (each 20 rats): the 1st group was normal rats, while the 2 nd was streptozotocin (STZ) diabetic rats and the 3 rd was diabetic rats treated with a single intravenous dose of bone marrow mesenchymal stromal cells (BM-MSCs) after 3 days from STZ induction. Results indicated that STZ induced DN represented by weight loss, hyperglycemia, hypoinsulineamia, decreased glycated hemoglobin, leukocytosis and impairment of kidney function and oxidative stress in kidney tissue. After BM-MSCs treatment, blood glucose level was improved, renal function was retained, body weight loss was decreased, insulin level and HBA1C percent were ameliorated with improved oxidative stress in kidney tissue. BM-MSCs have the capacity to regenerate and differentiate into insulin-producing cells improving DM and DN.
Introduction
Diabetes mellitus is followed by several complications mainly diabetic nephropathy (DN) [1] , which leads to renal disease in late stage and consequently increases both morbidity and mortality in diabetic cases [2, 3] . Oxidative stress is a major factor in diabetic vascular complications including DN [4, 5] as it leads to disturbance in the detoxification of reactive oxygen species (ROS) by the body which controls any damage. ROS regulates some genes and proteins that cause morphological and structural cell damage. Glycemic control may decrease the oxidative stress as it causes reduction of producing the intracellular reactive oxygen species [6] . Common therapies involve intensive control of hyperglycemia and hypertension but have no effect on diabetic nephropathy [7] , so there is an important need to explore new method targeting DN.
Stem cell therapy is used as a regenerative therapy in many diseases because of its selfrenewal and differentiation properties [8, 9] thus, it has the potential to be more effective than other drug therapies [10] . The most available type of these cells is mesenchymal stromal cell (MSCs), which easily obtained from human (blood, dermis, bone, bone marrow, adipose tissue and muscles) and has the ability to differentiate into other tissues as muscle, fat, cartilage and bone [11] [12] [13] . In the current study, we aimed to investigate the pancreatic and renoprotective effects of autologous transplantation of mesenchymal stromal cells derived from bone marrow (BM) in rats with streptozotocin (STZ) induced nephropathy.
Material and Methods

Experimental design
The current study was carried out on 60 male albino rats with body weight of 200±20g obtained from Standard Animal Laboratory Colony, Helwan, Cairo, Egypt. They were provided with ad libitum standard chow and water throughout the study. Rat model was performed by the Intra-peritoneal (IP) injection of 60 mg/kg STZ (Sigma-Aldrich, USA) [14] for the induction of type 1 and type 2 diabetes. After 7 days for proliferation and following one night of fasting, diabetes was confirmed by measuring fasting blood sugar of reading >250 mg/dL for 3 continuous days. Male rats were divided into 3 groups (each 20 rats): the 1 st group was non-diabetic rats received only vehicle, while the 2 nd group was rat of type 1 diabetes that induced by I/P injection of a single dose of STZ and not treated and the 3 rd group was diabetic rats, which received intravenous injection (I.V) of BM-MSCs in a single dose of 10 6 cells/rat in 1 mL serum free medium (GIBCO) after 3 days from the induction of STZ.
Culture, characterization and labeling of MSCs
Bone marrow was collected and cultured for 14 days on Dulbicco′s Modified Eagle′s Medium (DMEM) supplemented with 10 % fetal bovine serum after flushing the femurs and tibiae of 6 male rats [15] . MSCs were identified by their adhesiveness and fusiform shape. Red fluorescent cell linker (PKH26) was used in the labeling process [16] with transduction method (Sigma, Saint Louis, Missouri, USA) according to the manufacturer's recommendations.
Sample collection and analysis
Blood samples were collected for separation of serum from the retro-orbital venous sinus after 4 weeks from STZ injection for testing the biochemical parameters and blood samples for measuring hematological parameters. Kidneys were removed and divided into two parts; the first part was preserved frozen at -80 [25] ), the total superoxide dismutase (SOD) activity (xanthine oxidase method [26] ) and reduced glutathione content of kidney homogenate (Ellman's method [27] ) were measured with commercially available kits (Biodiagnostic Co. Cairo Egypt)
Statistical analysis
All data were represented by mean ± SE using Prism version 7 program. One-way ANOVA analysis was used to compare the different experimental groups. 6 cells/rat in 1 mL serum free medium (GIBCO) after 3 days from the induction of STZ. Means carrying different superscript within the same row were significant different at p < 0.05.
Results and Discussion
Four weeks after STZ injection, rats in the DN group showed light body weight and high blood sugar (P < 0.05) when compared with the non-diabetic group, while rats of the BMMSCs treated group revealed heavy body weight and low blood sugar (P < 0.05) when compared with the DN group (Table 1) . Glycated hemoglobin showed a higher increase (P < 0.05) in the DN group when compared with the non-diabetic group, however it was significantly lower in the BMMSCs group when compared with the DN group. Moreover, insulin was significantly decreased in the DN group when compared with the control one, while, it showed ameliorative effect in the treated group compared with DN group (Table 1) . The serum urea and creatinine levels in the DN rats were higher than the non-diabetic rats and their levels were significantly reduced after the injection of BM-MSCs when compared with DN group (Table 2) . Our results suggested that, BM-MSCs was able to control the alteration of the oxidative stress in the kidney homogenate of diabetic rats where the treated group exhibited a significant increase (P < 0.05) in the SOD activity and the GSH concentrations when compared with the DN group. In addition, the MDA concentration showed a significant decrease (P < 0.05) in the BM-MSCs treated group when compared with DN group (Table  2) . These results were confirmed with the improvement in the histological examination of pancreas and kidney after BM-MSCs treatment ( Figure 1) .
As a result of immunohistochemical (IHC) examination, there was small islets regeneration in the BMMSCs treated group (Figure 2) confirmed by the improvement in insulin levels and blood glucose levels, which indicated the beneficial role of MSCs in amelioration of DN. The islets regeneration indicated also by morphometric analysis showed that the nuclear size and length of islet cell increased significantly after BM-MSCs transplantation when compared with the DN group (Table 3) . 6 cells/rat in 1 mL serum free medium (GIBCO) after 3 days from the induction of STZ. Means carrying different superscript within the same row were significant different at p < 0.05. Supporting to our results, blood sugar was reduced by a single injection of MSCs in STZ-induced diabetic rats [28, 29] . Also, the intravenous injection of adipose-derived mesenchymal stem cells (ADMSC) in diabetic mice could significantly decrease the fasting blood sugar level and increase the secretion of insulin in the islet β-cells [30] . A previous study was performed by Tsai et al. [31] who found that mesenchymal stem cells (MSCs) derived from the human bone marrow were differentiated into new pancreatic cells alleviated the increase in blood glucose in diabetic group. On similar ground, a streptozotocin (STZ) diabetic rat model treated with MSC injection at the early (7 days) and late phase (21 days) could be able to control the hyperglycemia in diabetic rats with type 2 [32] . Zhang, et al. [33] reported that the increased blood glucose was associated with the decreased insulin secretion in the diabetic rats when compared with the non-diabetic rats and it was improved after treated with MSCs, which represented by tubular dilatation, mesangial expansion and glomerular sclerosis observed histopathologically under light microscope. Similar to our result, Lee et al. [34] and Ezquer et al. [35] showed that hyperglycemia and renal histology of diabetic rat was improved by MSC therapy when compared with the DN group. Lang and Dai [36] study showed that, there was an increase in the mesangial cells and mesangial matrix in diabetic rats when compared with the non-diabetic rats whereas in the MSC group, the histopathological changes were improved inhibiting the renal fibrosis compared with the DN group. Serum urea and creatinine were lowered after the BM-MSCs treatment due to the decrease protein degradation and the increase of their clearance by the kidney [37] . In contrary with our study, compared with the DN group, the single transplantation of MSCs didn't affect blood glucose levels in diabetic rats, whereas repeated injection for 7 days could significantly control it [38] . Moreover, a study of Ezquer et al. [39] demonstrated that, administration of MSCs in a mouse model did not result in hyperglycemia correction. In addition, Wang et al. [12] provided clear evidence that the injected MSCs prevented the development of albuminuria and loss of podocytes but there was no improvement in blood sugar levels. MSCs was used to ameliorate hyperglycemia, suppress oxidative stress in kidney homogenate and improve renal histopathological changes in diabetic rats with DN [40] . Liu et al. [41] reported that the IHC of the DN group showed mild cytoplasmic reactivity to insulin antibodies when compared with the control group and after treated with BM-MSCs, the pancreatic tissue showed marked reactivity to insulin antibodies (more than 75% of Islets' cells) when compared with the DN group, which supported our findings.
Conclusion
Bone marrow mesenchymal stromal cells had the ability to renew into islet cells and were differentiated into functional insulin secreting cells, which indicated its beneficial effects on diabetes-induced nephropathy and strongly recommended BM-MSCs in treating clinical cases of DM and DN as a future therapy. 
